New Two-Pronged attack on tough cancers enters Mid-Stage testing
NCT ID NCT06475300
Summary
This study is testing whether a new drug called BL-B01D1 works better when combined with an existing immunotherapy (PD-1 antibody) to control advanced cancers that have spread. It will involve about 570 adults with non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors to see if the combination shrinks tumors and is safe. The main goals are to find the right dose and measure how many patients' tumors respond to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.